Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 381

1.

NP108, an antimicrobial polymer with activity against methicillin and mupirocin resistant <i>Staphylococcus aureus</i>.

Mercer DK, Katvars LK, Hewitt F, Smith DW, Robertson J, O'Neil DA.

Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00502-17. doi: 10.1128/AAC.00502-17. [Epub ahead of print]

2.

Identification of a distinctive phenotype for endocarditis-associated clonal complex 22 MRSA isolates with reduced vancomycin susceptibility.

Marbach H, Boakes E, Lynham S, Ward M, Otter JA, Edgeworth JD.

J Med Microbiol. 2017 May;66(5):584-591. doi: 10.1099/jmm.0.000470. Epub 2017 May 15.

PMID:
28504620
3.

Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.

Stewart CL, Turner MS, Frens JJ, Snider CB, Smith JR.

Infect Dis Ther. 2017 Jun;6(2):277-289. doi: 10.1007/s40121-017-0156-z. Epub 2017 Apr 6.

4.

High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus.

San-Juan R, Fernández-Ruiz M, Gasch O, Camoez M, López-Medrano F, Domínguez MÁ, Almirante B, Padilla B, Pujol M, Aguado JM; REIPI/GEIH Study Group.

J Antimicrob Chemother. 2017 Mar 31. doi: 10.1093/jac/dkx096. [Epub ahead of print]

PMID:
28379553
5.

Clinical impact and prevalence of MRSA CC398 and differences between MRSA-TetR and MRSA-TetS in an area of Spain with a high density of pig farming: a prospective cohort study.

Reynaga E, Torres C, Garcia-Nuñez M, Navarro M, Vilamala A, Puigoriol E, Lucchetti GE, Sabrià M.

Clin Microbiol Infect. 2017 Mar 29. pii: S1198-743X(17)30188-X. doi: 10.1016/j.cmi.2017.03.019. [Epub ahead of print]

PMID:
28365311
6.

Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality.

Bassetti M, Peghin M, Trecarichi EM, Carnelutti A, Righi E, Del Giacomo P, Ansaldi F, Trucchi C, Alicino C, Cauda R, Sartor A, Spanu T, Scarparo C, Tumbarello M.

PLoS One. 2017 Feb 2;12(2):e0170236. doi: 10.1371/journal.pone.0170236. eCollection 2017.

7.

Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.

Arshad S, Huang V, Hartman P, Perri MB, Moreno D, Zervos MJ.

Int J Infect Dis. 2017 Apr;57:27-31. doi: 10.1016/j.ijid.2017.01.019. Epub 2017 Jan 25.

8.

Invasive Systemic Infection After Hospital Treatment for Diabetic Foot Ulcer: Risk of Occurrence and Effect on Survival.

Chen SY, Giurini JM, Karchmer AW.

Clin Infect Dis. 2017 Feb 1;64(3):326-334. doi: 10.1093/cid/ciw736. Epub 2016 Nov 10.

PMID:
28013263
9.

Thrombocytopaenia during methicillin-sensitive Staphylococcus aureus bacteraemia.

Forsblom E, Tielinen I, Ruotsalainen E, Järvinen A.

Eur J Clin Microbiol Infect Dis. 2017 May;36(5):887-896. doi: 10.1007/s10096-016-2877-4. Epub 2016 Dec 23.

PMID:
28012099
10.

Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, Klinker KP, Davis SL, Rybak MJ.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e02015-16. doi: 10.1128/AAC.02015-16. Print 2017 Feb.

PMID:
27895012
11.

Epidemiology and Mortality of Staphylococcus aureus Bacteremia in Australian and New Zealand Children.

McMullan BJ, Bowen A, Blyth CC, Van Hal S, Korman TM, Buttery J, Voss L, Roberts S, Cooper C, Tong SY, Turnidge J.

JAMA Pediatr. 2016 Oct 1;170(10):979-986. doi: 10.1001/jamapediatrics.2016.1477.

PMID:
27533601
12.

Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Claeys KC, Zasowski EJ, Casapao AM, Lagnf AM, Nagel JL, Nguyen CT, Hallesy JA, Compton MT, Kaye KS, Levine DP, Davis SL, Rybak MJ.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5841-8. doi: 10.1128/AAC.00227-16. Print 2016 Oct.

13.

Time trends in Staphylococcus aureus bacteremia, 1988-2010, in a tertiary center with high methicillin resistance rates.

Yahav D, Shaked H, Goldberg E, Yassin S, Eliakim-Raz N, Paul M, Bishara J, Leibovici L.

Infection. 2017 Feb;45(1):51-57. doi: 10.1007/s15010-016-0919-6. Epub 2016 Jul 13.

PMID:
27411532
14.

Infective endocarditis in patients on haemodialysis - possible strategies for prevention.

Oun HA, Price AJ, Traynor JP.

Scott Med J. 2016 May;61(2):97-102. Epub 2016 Jun 22.

PMID:
27334533
16.

Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections.

Gonzalez-Ruiz A, Seaton RA, Hamed K.

Infect Drug Resist. 2016 Apr 15;9:47-58. doi: 10.2147/IDR.S99046. eCollection 2016. Review.

17.

Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia.

Wong D, Wong T, Romney M, Leung V.

Ann Clin Microbiol Antimicrob. 2016 Apr 26;15:27. doi: 10.1186/s12941-016-0143-3.

18.

Successful Use of High-dose Daptomycin in a Child With Staphylococcus aureus Endocarditis.

Prabhudesai S, Kanjani A, Nambi PS, Gnanasambandam S, Ramachandran B.

Pediatr Infect Dis J. 2016 May;35(5):517-8. doi: 10.1097/INF.0000000000000958.

PMID:
27074655
19.

Empirical therapy in Methicillin-resistant Staphylococcus Aureus infections: An Up-To-Date approach.

VanEperen AS, Segreti J.

J Infect Chemother. 2016 Jun;22(6):351-9. doi: 10.1016/j.jiac.2016.02.012. Epub 2016 Apr 8. Review.

PMID:
27066882
20.

Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin.

Browne C, Muszbek N, Chapman R, Marsh K, Gould IM, Seaton RA, Allen M.

Int J Antimicrob Agents. 2016 May;47(5):357-61. doi: 10.1016/j.ijantimicag.2016.02.006. Epub 2016 Mar 19.

PMID:
27061774

Supplemental Content

Loading ...
Support Center